Back to Search
Start Over
Myeloid derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL-1β, IL-8, CXCL5 and Mip-1α
- Publication Year :
- 2016
-
Abstract
- Purpose: Little is known about the association between myeloid-derived suppressor cell (MDSC) subsets and various chemokines in patients with renal cell carcinoma (RCC) or the factors that draw MDSC into tumor parenchyma. Experimental Design: We analyzed polymorphonuclear MDSC (PMN-MDSC), monocytic MDSC (M-MDSC), and immature MDSC (I-MDSC) from the parenchyma and peripheral blood of 48 patients with RCC, isolated at nephrectomy. We analyzed levels of IL1β, IL8, CXCL5, Mip-1α, MCP-1, and Rantes. Furthermore, we performed experiments in a Renca murine model to assess therapeutic synergy between CXCR2 and anti-PD1 and to elucidate the impact of IL1β blockade on MDSC. Results: Parenchymal PMN-MDSC have a positive correlation with IL1β, IL8, CXCL5, and Mip-1α, and I-MDSC correlate with IL8 and CXCL5. Furthermore, peripheral PMN-MDSC correlate with tumor grade. Given that PMN-MDSC express CXCR2 and parenchymal PMN-MDSC correlated with IL8 and CXCL5, we assessed the response of CXCR2 blockade with or without anti-PD1. Combination therapy reduced tumor weight and enhanced CD4+ and CD8+ T-cell infiltration. In addition, anti-IL1β decreased PMN-MDSC and M-MDSC in the periphery, PMN-MDSC in the tumor, and peripheral CXCL5 and KC. Anti-IL1β also delayed tumor growth. Conclusions: Parenchymal PMN-MDSC have a positive correlation with IL1β, IL8, CXCL5, and Mip-1α, suggesting they may attract PMN-MDSC into the tumor. Peripheral PMN-MDSC correlate with tumor grade, suggesting prognostic significance. Anti-CXCR2 and anti-PD1 synergized to reduce tumor weight and enhanced CD4+ and CD8+ T-cell infiltration in a Renca murine model, suggesting that CXCR2+ PMN-MDSC are important in reducing activity of anti-PD1 antibody. Finally, anti-IL1β decreases MDSC and delayed tumor growth, suggesting a potential target for MDSC inhibition. Clin Cancer Res; 23(9); 2346–55. ©2016 AACR.
- Subjects :
- 0301 basic medicine
Cancer Research
Chemokine
Pathology
medicine.medical_specialty
Chemokine CXCL5
Interleukin-1beta
Programmed Cell Death 1 Receptor
Article
Monocytes
Receptors, Interleukin-8B
03 medical and health sciences
Mice
0302 clinical medicine
Renal cell carcinoma
Cell Line, Tumor
Parenchyma
Antineoplastic Combined Chemotherapy Protocols
Carcinoma
medicine
Animals
Humans
CXC chemokine receptors
Carcinoma, Renal Cell
Parenchymal Tissue
Chemokine CCL3
biology
business.industry
Myeloid-Derived Suppressor Cells
Interleukin-8
hemic and immune systems
medicine.disease
Tumor Burden
Gene Expression Regulation, Neoplastic
030104 developmental biology
Oncology
CXCL5
030220 oncology & carcinogenesis
Myeloid-derived Suppressor Cell
biology.protein
business
CD8
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....28d9d5afc7b4f9758b17046d29220f1b